Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib plus lenalidomide and dexamethasone versus placebo plus lenalidomide and dexamethasone in newly diagnosed multiple myeloma
2013-000326-54Phase 3Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple myeloma (MM) comparing Ixazomib + lenalidomide + dexamethasone with Placebo + lenalidomide + dexamethasone (2 arms). Primary endpoint: Progression-free survival. Started Apr 2013; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2013-000326-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000326-54.